Orgenesis Inc. (ORGS) News

Orgenesis Inc. (ORGS): $4.13

0.24 (-5.49%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

F

Add ORGS to Watchlist
Sign Up

Filter ORGS News Items

ORGS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ORGS News From Around the Web

Below are the latest news stories about ORGENESIS INC that investors may wish to consider to help them evaluate ORGS as an investment opportunity.

Analysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven Soon

Orgenesis Inc. ( NASDAQ:ORGS ) is possibly approaching a major achievement in its business, so we would like to shine...

Yahoo | November 22, 2023

Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM

GERMANTOWN, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced it ranked 171 on the Deloitte Technology Fast 500™, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year. Vered Caplan, CEO of Orgenesis, commented, “We are very proud

Yahoo | November 14, 2023

Orgenesis Provides Business Update for the Third Quarter of 2023

Advances rollout of POCare Platform and POCare TherapiesGERMANTOWN, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the third quarter ended September 30, 2023. Vered Caplan, CEO of Orgenesis, said, “We continue to advance the commercial launch of our POCare Platform through Octomera, building out a decentralized

Yahoo | November 13, 2023

Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering

GERMANTOWN, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (“Orgenesis”) (Nasdaq: ORGS), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.1 million of its common stock and warrants to purchase common stock in a registered direct offering. The combined effective purchase price for each share of common stoc

Yahoo | November 8, 2023

Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding

GERMANTOWN, Md., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today announced continued progression of the Point of Care (POCare) network and infrastructure for the advanced therapeutic services and facilities business through its subsidiary Octomera. The teams have been confirmed as an industrial partner to the University of California Davis, a lead

Yahoo | November 2, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time for another busy day of trading as we go over the biggest pre-market stock movers worth watching on Tuesday morning!

William White on InvestorPlace | October 31, 2023

Orgenesis Announces Withdrawal of Proposed Public Offering

GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced that it has withdrawn its previously announced proposed underwritten public offering of securities due to market conditions. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall ther

Yahoo | October 31, 2023

Orgenesis Announces Proposed Underwritten Public Offering

GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced it has commenced an underwritten public offering. Orgenesis intends to use the net proceeds from the offering for working capital and general corporate purposes. EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book-running manager for the offering. T

Yahoo | October 30, 2023

CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States

GERMANTOWN, Maryland, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the Point of Care (POCare) network and infrastructure of its advanced therapeutic services and facilities business through its subsidiary Octomera, by partnering with CGT Global, a biomedical company dedicated to advancing medical science and patient therapies. The

Yahoo | September 21, 2023

Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support

Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support GERMANTOWN, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies

Yahoo | September 6, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!